Academic Journal
Randomized controlled pilot trial of prazosin for prophylaxis of posttraumatic headaches in active‐duty service members and veterans
| العنوان: | Randomized controlled pilot trial of prazosin for prophylaxis of posttraumatic headaches in active‐duty service members and veterans |
|---|---|
| المؤلفون: | Mayer, Cindy L., Savage, Paul J., Engle, Conner K., Groh, Soleil S., Shofer, Jane B., Hargrove, Ameryth M., Williams, Tammy J., Poupore, Eileen L., Hart, Kimberly L., Riechers, Ronald G., Ruff, Robert L., Peskind, Elaine R., Raskind, Murray A. |
| المساهمون: | U.S. Department of Defense |
| المصدر: | Headache: The Journal of Head and Face Pain ; volume 63, issue 6, page 751-762 ; ISSN 0017-8748 1526-4610 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2023 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Objective Evaluate the efficacy and tolerability of prazosin for prophylaxis of headaches following mild traumatic brain injury in active‐duty service members and military veterans. Background Prazosin is an alpha‐1 adrenoreceptor antagonist that reduces noradrenergic signaling. An open‐label trial in which prazosin reduced headache frequency in veterans following mild traumatic brain injury provided the rationale for this pilot study. Methods A 22‐week parallel‐group randomized controlled trial which included 48 military veterans and active‐duty service members with mild traumatic brain injury–related headaches was performed. The study design was based on International Headache Society consensus guidelines for randomized controlled trials for chronic migraine. Following a pre‐treatment baseline phase, participants with at least eight qualifying headache days per 4 weeks were randomized 2:1 to prazosin or placebo. After a 5‐week titration to a maximum possible dose of 5 mg (morning) and 20 mg (evening), participants were maintained on the achieved dose for 12 weeks. Outcome measures were evaluated in 4‐week blocks during the maintenance dose phase. The primary outcome measure was change in 4‐week frequency of qualifying headache days. Secondary outcome measures were percent participants achieving at least 50% reduction in qualifying headache days and change in Headache Impact Test‐6 scores. Results Intent‐to‐treat analysis of randomized study participants (prazosin N = 32; placebo N = 16) demonstrated greater benefit over time in the prazosin group for all three outcome measures. In prazosin versus placebo participants, reductions from baseline to the final rating period for 4‐week headache frequency were −11.9 ± 1.0 (mean ± standard error) versus −6.7 ± 1.5, a prazosin minus placebo difference of −5.2 (−8.8, −1.6 [95% confidence interval]), p = 0.005 and for Headache Impact Test‐6 scores were −6.0 ± 1.3 versus +0.6 ± 1.8, a difference of −6.6 (−11.0, −2.2), p = 0.004. The mean predicted percent of ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1111/head.14529 |
| الاتاحة: | http://dx.doi.org/10.1111/head.14529 https://headachejournal.onlinelibrary.wiley.com/doi/am-pdf/10.1111/head.14529 |
| Rights: | http://onlinelibrary.wiley.com/termsAndConditions#am ; http://onlinelibrary.wiley.com/termsAndConditions#vor |
| رقم الانضمام: | edsbas.81B31CB4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/head.14529 |
|---|